Navigation Links
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
Date:2/27/2008

r therapies.

Safety findings in the study were manageable and consistent with prior Phase II studies. Common adverse events in the study included mouth ulcers, high blood lipids, high blood sugar, skin rash, low red blood count, low phosphate levels, and inflammation of the lungs.

About Everolimus

Everolimus, an oral inhibitor of mTOR, is an investigational drug being studied in multiple tumor types. In cancer cells, everolimus inhibits mTOR, a protein that acts as a central regulator of tumor cell division, cell metabolism and blood vessel growth. Everolimus is a once-daily oral therapy that provides continuous inhibition of mTOR.

As an investigational compound, the safety and efficacy profile of everolimus has not yet been established in oncology. Access to everolimus is available only through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the compound. Because of the uncertainty of clinical trials, there is no guarantee that everolimus will ever be commercially available for oncology indications anywhere in the world. Everolimus is approved under the trade-name Certican(R) for the prevention of organ rejection in heart and kidney transplant recipients. Certican was first approved in the EU in 2003 and is available in more than 60 countries.

Disclaimer

The foregoing release contains forward-looking statements that can be identified by terminology such as "to be", "planned", "may", "offers", "potential", "could", "possibilities", "will", or similar expressions, or by express or implied discussions regarding potential future approvals for everolimus or regarding potential future revenues from everolimus. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with everolimus to be materially differen
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. Phase I and Phase I/II DCVax(R)-Brain Data Continues to Show Significantly Improved Survival Rates for Brain Cancer Patients
3. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
4. TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil
5. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
6. Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
7. New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings
8. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
9. CV Therapeutics Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
10. VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis
11. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Rock Creek Pharmaceuticals, ... company, today announced that the Food and Drug Administration ... provide comments on RCP,s Investigational New Drug ("IND") application ... trial in the US. Dr. Chris ... review and comments on our IND. When we receive ...
(Date:7/11/2014)... , July 11, 2014  Australian drug delivery company, ... it has raised A$19.3 million via a placement of ... , the U.S., Asia ... from a share purchase plan (SPP) to be offered ... be made in two tranches. "This capital ...
(Date:7/11/2014)... Show organisers report ... Expo 2014 were a brand new audience ... London , plus a 10% increase ...      (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ...      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ) ...
Breaking Medicine Technology:Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
... SAN FRANCISCO, Calif., Feb. 9, 2011 Rigel Pharmaceuticals, ... James M. Gower, the company,s chairman and chief executive ... in New York City next week. Details of the ... ET13th Annual BIO CEO & Investor ConferencePanel Topic:  "Rheumatoid ...
... announces that a new market research report is ... Pacific Markets for Orthopedic Large Joint Reconstructive Devices ... In 2010, the combined markets for large ... were valued at over US$1.65 billion. ...
Cached Medicine Technology:Rigel Announces Participation at Two Investor Conferences 2Reportlinker Adds Asia Pacific Markets for Orthopedic Large Joint Reconstructive Devices 2011 2
(Date:7/13/2014)... The Lancet Neurology calls for sports authorities ... problems that repeated concussions can cause. , Cerebral ... traumatic brain injury (TBI), and the long-term effects ... sclerosis, and other neurological disorders, say the journal ... that even when the symptoms of concussion are ...
(Date:7/13/2014)... in Nature Genetics identifies a novel ... causes eosinophillic esophagitis (EoE), opening up potential new ... allergy. , EoE is a chronic inflammatory ... by allergic hypersensitivity to certain foods and an ... called eosinophils (part of the body,s immune system). ...
(Date:7/13/2014)... North American water storage systems market is estimated to grow ... at a CAGR of 21.0%, from 2013 to 2018. The ... in North America. The U.S. is experiencing high growth on ... and collection, and the increased spending on modernization and upgradation ... rate in Canada, and is rising at a rapid pace ...
(Date:7/13/2014)... 2014 According to a new ... Market by Component (processor, GPU, DSP, connectivity), Technology ... and Geography - Forecast and Analysis to 2014-2020", ... & Computing Market is expected to reach $61.70 ... 20.75% from 2014 to 2020. , Browse 71 ...
(Date:7/13/2014)... 2014 Athletes with a certain genetic ... concussions, according to research presented today at the American ... Meeting. The research marks the first of its kind ... known physical events that occur after a head injury. ... allele in the (GT)n genotype were four times more ...
Breaking Medicine News(10 mins):Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2
... choose and eat more indulgent food after they see someone who ... a new study in the Journal of Consumer Research . ... evening with friends and realize that they ate more and worse ... (Leeds School of Business) and Gina S. Mohr (University of Colorado, ...
... people are more likely to eat candy bars, whereas hopeful ... Journal of Consumer Research . That,s because when people ... us are aware that we often fall victim to emotional ... or healthy snacks when we,re feeling good?" write authors Karen ...
... Jason S. Meyer, Ph.D., assistant professor of biology in ... will be honored by the largest eye and vision ... day may lead to reversal of blindness caused by ... retina. The Association for Research in Vision ...
... By identifying a surprising association of two intracellular proteins, ... the development of new therapies to treat B cell ... B cells expressing the viral protein Latent Membrane Protein ... of cancer because of its role in the proliferation ...
... have shown for the first time how peppermint helps ... 20% of the population. In a paper published ... researchers from the University,s Nerve-Gut Research Laboratory explain how ... inflammatory pain in the gastrointestinal tract. Dr Stuart ...
... News) -- Swedish tourists who saw the most severe ... tsunami have taken longer than their peers to recover ... associated with increased levels of post-traumatic stress reactions, even ... study led by Kerstin Bergh Johannesson of Uppsala University ...
Cached Medicine News:Health News:Does seeing overweight people make us eat more? 2Health News:Why do hopeful consumers make healthier choices than happy ones? 2Health News:IUPUI faculty member to receive national innovative vision research award 2Health News:Discovery of relationship between proteins may impact development of cancer therapies 2Health News:Peppermint earns respect in mainstream medicine 2Health News:Mental Health Effects Linger After Tsunami, Study Finds 2
Abdominal Binder w / Velcro...
CDIs Abdominal Binders are designed with a non-pitching, body contouring, non-rolling elastic band that provides both support and compression. Available in 9, 12 and 15 widths with waist ranges from ...
Ideal for abdominal, flank, hip and thigh procedures....
Ideal for abdominal and flank procedures....
Medicine Products: